Pyxis Oncology, INC

Pyxis Oncology announced updated Phase 1 data for its drug candidate micvotabart pelidotin (MICVO) in head and neck cancer, showing a 36% objective response rate and a 94% disease control rate.

Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, reinforcing its focus on advancing its MICVO program.

Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.

Pyxis Oncology announced a $50 million private placement financing to advance its lead drug candidate, MICVO, through key clinical milestones.

Pyxis Oncology, Inc. announced the results of its Annual Meeting of Stockholders held on June 15, 2026, including the election of directors and ratification of its independent auditor.

Pyxis Oncology announced its first quarter 2026 financial results, highlighting progress in its micvotabart pelidotin (MICVO) clinical development program and providing an updated cash runway into Q4 2026.

Pyxis Oncology reports continued operating losses and substantial R&D expenses, raising concerns about its ability to continue as a going concern despite a recent private placement.

Pyxis Oncology filed its Q1 2026 Form 10-Q, detailing a net loss of $23.3 million and highlighting progress in its MICVO clinical development programs.

Pyxis Oncology reported increased net losses and a going concern warning, while advancing its lead oncology candidate, micvotabart pelidotin, with positive preliminary HNSCC clinical data and Fast Track Designation.

Pyxis Oncology reported increased losses in Q2 2025 but highlighted positive clinical data and Fast Track designation for its lead oncology candidate, micvotabart pelidotin.

Pyxis Oncology's Q1 2025 results show a net loss of $21.2 million, with strategic focus shifting towards advancing micvotabart pelidotin, particularly in R/M HNSCC.

Pyxis Oncology reports a net loss of $41.8 million for the nine months ended September 30, 2024, while highlighting progress in its clinical programs for PYX-201 and PYX-106.

Pyxis Oncology announced positive preliminary Phase 1 data for its lead oncology candidate MICVO in HNSCC, both as monotherapy and in combination with KEYTRUDA, but reported significant losses and substantial doubt about its ability to continue as a going concern.

Pyxis Oncology focuses on advancing its lead candidate, micvotabart pelidotin, for head and neck cancer treatment following encouraging Phase 1 trial results, while reporting a net loss of $77.3 million for 2024.

Pyxis Oncology's annual 10-K filing details the company's clinical progress, financial status, and strategic direction, highlighting its focus on novel cancer therapeutics.

Thomas Civik, CEO & Chairman of the Board and a Director of Pyxis Oncology, Inc., received 2,503,050 shares of common stock on September 4, 2026.

Jakob Dupont, a Director of Pyxis Oncology, Inc., received 46,000 shares of common stock on August 20, 2026.

Jakob Dupont, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology's Principal Financial & Accounting Officer, Jitendra Wadhane, received grants of 109,461 restricted stock units and 262,635 stock options.

Pyxis Oncology's Director, John L. Flavin, was granted 45,867 stock options with an exercise price of $1.36, vesting fully on the first anniversary of the grant date.

Michael A. Metzger, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 15, 2026, to elect directors and ratify auditor appointment.

Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Pyxis Oncology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections and auditor ratification.

Pyxis Oncology is asking stockholders to approve an amendment to its 2021 Equity and Incentive Plan to increase the available shares by 5,500,000 at a special meeting on October 23, 2024.

Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Pyxis Oncology announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, to vote on director elections and the ratification of its independent accounting firm.

Pyxis Oncology, Inc.'s President, CEO, and Chief Medical Officer, Lara Sullivan, has increased her beneficial ownership to 11.21% of the company's common stock following a new stock option grant.

Several Biotechnology Value Funds and Mark N. Lampert have jointly filed a Schedule 13G, disclosing beneficial ownership of Pyxis Oncology, Inc. common stock and warrants.

GordonMD Global Investments LP and affiliated entities report beneficial ownership of 10,024,909 shares, representing 12.1% of Pyxis Oncology, Inc.'s common stock.

Laurion Capital Management LP and its co-managing members have disclosed a 7.72% beneficial ownership stake in Pyxis Oncology, Inc., totaling 4,796,479 shares of common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported a 1.3% beneficial ownership stake in Pyxis Oncology, Inc. as of September 30, 2025.

GordonMD Global Investments LP and its affiliates have reported a 6.2% beneficial ownership stake in Pyxis Oncology, Inc., totaling 3,834,740 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Pyxis Oncology, Inc. as of June 30, 2025.